Loading publications…
The last 5 uploaded publications
Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G. Singal, Eli Pikarsky, Sasan Roayaie, Riccardo Lencioni, Kazuhiko Koike, Jessica Zucman‐Rossi, Richard S. Finn (2021). Hepatocellular carcinoma. Nature Reviews Disease Primers, 7(1), DOI: 10.1038/s41572-020-00240-3.
Article145 days agoRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gérolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han (2016). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10064), pp. 56-66, DOI: 10.1016/s0140-6736(16)32453-9.
Article145 days agoMolecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, Richard S. Finn (2018). Molecular therapies and precision medicine for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 15(10), pp. 599-616, DOI: 10.1038/s41571-018-0073-4.
Article145 days agoRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, P. Abada, Masatoshi Kudo (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(2), pp. 282-296, DOI: 10.1016/s1470-2045(18)30937-9.
Article145 days agoImmunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, Mala K. Maini, Vincenzo Mazzaferro, David J. Pinato, Eli Pikarsky, Andrew X. Zhu, Richard S. Finn (2021). Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 19(3), pp. 151-172, DOI: 10.1038/s41571-021-00573-2.
Article145 days ago